Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Thursday, January 23, 2020
Catalent supports the news that DiaMedica received FDA approval to commence Phase 2 clinical trials of DM199 for chronic kidney disease.
read more
Catalent plans to invest $30 million at its facility in Limoges, France, to create a European center of excellence for clinical biologics formulation development and drug product fill-finish services.
read more
Catalent Pharma Solutions and Valerius Biopharma announced that they are to collaborate on the development and manufacture of Valerius’ biosimilar products.
read more
Catalent held a ground breaking ceremony at its Bloomington, Indiana site to mark the start of construction on a $112 million drug product manufacturing facility.
read more
Catalent Pharma Solutions announced the completion of its new, 30,000-square-foot clinical supply facility in Shanghai, China.
read more
Catalent Pharma Solutions has signed a multi-year agreement with Grid Therapeutics, for the development and manufacture of Grid’s lead therapeutic candidate for the treatment of solid tumors.
read more
Catalent announced it began Phase 2 clinical trials of MGB Biopharma.
read more
Tuesday, January 25, 2022
Catalent announced that it has completed a $10 million expansion in state-of-the-art large-scale isolator units at its Malvern, Pennsylvania, and Dartford, U.K., facilities, to provide advanced containment capabilities for the micronization of highly...
read more
Wednesday, February 28, 2018
Catalent Pharma Solutions announced the completion of a two-year, $4.6 million expansion at its Singapore clinical supply facility.
read more
Catalent Pharma Solutions has completed a $5.5 million expansion program at its 200,000+ square foot Philadelphia, Pennsylvania, site to provide additional clinical packaging and storage capacity.
read more
Catalent Pharma Solutions has completed the second phase of a $5.5 million expansion program at its Kansas City, Missouri facility.
read more
Friday, February 17, 2017
Catalent has completed the acquisition of Accucaps Industries Limited (Accucaps), the Canada-based developer and manufacturer of Over-the-Counter (OTC), high-potency and conventional pharmaceutical softgels. Financial details of the transaction have ...
read more
Catalent has completed the $1.2 billion acquisition of Paragon Bioservices, a viral vector development and manufacturing partner for gene therapies.
read more
Tuesday, October 24, 2017
Catalent has completed the acquisition of Cook Pharmica, an integrated provider of drug substance and drug product manufacturing and related services.
read more
Friday, February 17, 2012
Catalent Pharma Solutions today announced that it has completed the acquisition of the Clinical Trial Supplies business of Aptuit LLC. The acquisition substantially expands Catalent’s Development & Clinical Services business, transforming it into the...
read more